Aktuellt
SENASTE
Fluoguide reported a Q2 EBIT loss of DKK 8.66m and a DKK 8.06m cash position, which excludes the DKK 15m raised in July and the additional DKK 25m in warrants that can be exercised in Nov-23. During the quarter, Fluoguide completed recruitment to its aggressive glioma trial and further positive data in its head and neck cancer ph2 trial were announced. On the back of this impressive progress, we expect to reiterate our equity valuation range (mid-point SEK 180 p.s.).
LÄS MER
